Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions he has had on the provision of Enhurtu to Her2 low metastatic breast cancer patients.

The Department’s ministers and officials have had a number of recent meetings at which the issue of the availability of Enhertu for the treatment of HER2 low metastatic breast cancer has been discussed, including with Breast Cancer Now and other campaigners.

The Government wants patients to be able to benefit from access to innovative and effective new treatments such as Enhertu at a price that fairly reflects the benefits that they bring to patients, and does not displace funding for other valuable treatments and services. The National Institute for Health and Care Excellence and NHS England have been clear with the companies that the price represents the main barrier to access to Enhertu for patients with HER2 low breast cancer, and we encourage the companies to come forward with an improved commercial offer.